In addition, intermittent parathyroid hormone (PTH) treatment -an anabolic agent for bone- used for treatment of osteoporosis, fails to reduce erosion volume in patients with established RA with disease activity controlled by TNF blockers (92). The gene discussed is PTH; the disease is osteoporosis.